ProCE Banner Activity

First-in-Human Phase I Trial of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With R/R MM

Slideset Download
Conference Coverage
Bispecific antibody targeting GPCR5D, talquetamab, appears tolerable, safe, and efficacious in phase I data in patients with heavily pretreated relapsed/refractory MM.

Released: December 11, 2020

Expiration: December 10, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology